Drug Profile

JMT 203

Alternative Names: JMT-203

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai JMT-BIO Technology
Class Monoclonal antibodies
Mechanism of Action Glial cell line-derived neurotrophic factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Cachexia

Most Recent Events

15 May 2024 Phase-I clinical trials in Cachexia in China (SC) (NCT06868849)
26 Jun 2023 CSPC Pharmaceutical Group Limited receives the clinical trial approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials of JMT 203 in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com